Back to Results
First PageMeta Content
Cytokines / Kidney diseases / Syndromes / Autoimmune diseases / Acquired hemolytic anemia / Interferon beta-1a / Biogen Idec / Thrombotic microangiopathy / Glomerulonephritis / Medicine / Health / Anatomy


Betaferon II-95 Final DHPC and Communication plan including reference to Plegridy
Add to Reading List

Document Date: 2014-10-14 07:41:24

Open Document

File Size: 248,03 KB

Share Result on Facebook

Company

Merck Serono Europe Ltd / Bayer Pharma AG / Bayer plc / Novartis Europharm Ltd / Novartis Pharmaceuticals UK Ltd / Ireland Biogen Idec Ltd / UK Company Biogen Idec Ltd / Biogen Idec Ltd / Merck Serono Ltd / /

Country

United Kingdom / /

/

IndustryTerm

treatment of multiple sclerosis / beta products / treatment of nephrotic syndrome / interferon beta products / interferon-beta products / interferonbeta product / medicinal products / /

MedicalCondition

focal segmental glomerulosclerosis / proteinuria / minimal change disease / nonspecific kidney disorder / urinary disorders / membranoproliferative glomerulonephritis / thrombotic thrombocytopenic purpura / thrombocytopenia / new onset hypertension / fever / nephrotic syndrome / congenital abnormality / multiple sclerosis / thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome / renal disease / occlusive microvascular thrombosis / paresis / haemolytic uraemic syndrome / membranous glomerulopathy / collapsing focal segmental glomerulosclerosis (FSGS) / /

MedicalTreatment

plasma exchange / /

Organization

European Medicines Agency / MHRA / Commission on Human Medicines / Medicines and Healthcare Products Regulatory Agency / /

Person

Fiona Thomas / Luis-Felipe Graterol / /

/

Position

Governor / Medical Director / Director Bayer / /

Product

Characteristics (SmPCs) / peginterferon / Package Leaflets (PLs) / Rebif / Avonex / /

URL

http /

SocialTag